Somatic and germline TP53 alterations in second malignant neoplasms from pediatric cancer survivors

Amy L. Sherborne, Vincent Lavergne, Katharine Yu, Leah Lee, Philip R. Davidson, Tali Mazor, Ivan V. Smirnoff, Andrew E. Horvai, Mignon Loh, Steven G. DuBois, Robert E. Goldsby, Joseph P. Neglia, Sue Hammond, Leslie L. Robison, Rosanna Wustrack, Joseph F. Costello, Alice O. Nakamura, Kevin M. Shannon, Smita Bhatia, Jean L. Nakamura

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Purpose: Second malignant neoplasms (SMNs) are severe late complications that occur in pediatric cancer survivors exposed to radiotherapy and other genotoxic treatments. To characterize the mutational landscape of treatment-induced sarcomas and to identify candidate SMN-predisposing variants, we analyzed germline and SMN samples from pediatric cancer survivors. Experimental Design:We performed whole-exome sequencing (WES) and RNA sequencing on radiation-induced sarcomas arising from two pediatric cancer survivors. To assess the frequency of germline TP53 variants in SMNs, Sanger sequencing was performed to analyze germline TP53 in 37 pediatric cancer survivors from the Childhood Cancer Survivor Study (CCSS) without any history of a familial cancer predisposition syndrome but known to have developed SMNs. Results: WES revealed TP53 mutations involving p530s DNAbinding domain in both index cases, one of which was also present in the germline. The germline and somatic TP53-mutant variants were enriched in the transcriptomes for both sarcomas. Analysis of TP53-coding exons in germline specimens from the CCSS survivor cohort identified a G215C variant encoding an R72P amino acid substitution in 6 patients and a synonymous SNP A639G in 4 others, resulting in 10 of 37 evaluable patients (27%) harboring a germline TP53 variant. Conclusions: Currently, germline TP53 is not routinely assessed in patients with pediatric cancer. These data support the concept that identifying germline TP53 variants at the time a primary cancer is diagnosed may identify patients at high risk for SMN development, who could benefit from modified therapeutic strategies and/or intensive posttreatment monitoring.

Original languageEnglish (US)
Pages (from-to)1852-1861
Number of pages10
JournalClinical Cancer Research
Issue number7
StatePublished - Apr 1 2017

Bibliographical note

Publisher Copyright:
© 2016 American Association for Cancer Research.


Dive into the research topics of 'Somatic and germline TP53 alterations in second malignant neoplasms from pediatric cancer survivors'. Together they form a unique fingerprint.

Cite this